Literature DB >> 2225710

Validity of creatinine clearance estimates in the assessment of renal function.

D R Luke1, C E Halstenson, J A Opsahl, G R Matzke.   

Abstract

In clinical practice, estimations of renal function are commonly used to calculate the appropriate dose for drugs that are renally cleared. Continuous-infusion inulin clearance (CLIN), 4-hour creatinine clearance (CLCR,m), and 24-hour creatinine clearance (CLCR,a) were measured in 109 subjects (86 men and 23 women) with varying degrees of stable renal function (CLIN, 6 to 209 ml/min) and compared with CLCR values as predicted by five equations on the basis of plasma creatinine concentrations, age, weight, and/or height. The CLCR,m was positively correlated with CLIN (r = 0.92; p less than 0.0001) but exceeded CLIN by 15% between the range of 30 and 209 ml/min (CLIN). Similarly, CLCR,a correlated well with both CLCR,m (r = 0.84; p less than 0.0005) and CLIN (r = 0.84; p less than 0.0001). The relative role of tubular secretion in the overall clearance of creatinine increased with declining CLIN and exceeded 40% when CLIN was below 30 ml/min. CLCR estimated by the Cockcroft-Gault and Mawer methods did not significantly differ from either CLCR,m or CLCR,m, whereas the other equations generally underestimated CLCR. Among the numerous mathematical equations, CLCR as estimated by the method proposed either by Mawer or Cockcroft and Gault was the best predictor of CLIN (CLIN = 1.05CLRCR - 18.38 or CLIN = 1.12CLCR - 20.60, respectively; r = 0.81; p less than 0.0001). The present data support the use of estimator equations proposed by Cockcroft and Gault or Mawer for rapid estimation of renal function in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225710     DOI: 10.1038/clpt.1990.186

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  29 in total

1.  Evaluation of renal function in patients with rheumatoid arthritis and amyloidosis.

Authors:  K Laiho; K Kaarela; H Kautianen; M Kauppi
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

2.  The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.

Authors:  Peter A Lockwood; Jack A Cook; Wayne E Ewy; Jaap W Mandema
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

3.  Difference in estimated GFR with two different formulas in elderly individuals.

Authors:  K Wieczorowska-Tobis; Z I Niemir; P Guzik; A Breborowicz; D G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

4.  Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.

Authors:  Meletios A Dimopoulos; Matthew C Cheung; Murielle Roussel; Ting Liu; Barbara Gamberi; Brigitte Kolb; H Guenter Derigs; HyeonSeok Eom; Karim Belhadj; Pascal Lenain; Richard Van der Jagt; Sophie Rigaudeau; Mamoun Dib; Rachel Hall; Henry Jardel; Arnaud Jaccard; Axel Tosikyan; Lionel Karlin; William Bensinger; Rik Schots; Nicolas Leupin; Guang Chen; Jennifer Marek; Annette Ervin-Haynes; Thierry Facon
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

Review 5.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

6.  Measurement Error as Alternative Explanation for the Observation that CrCl/GFR Ratio is Higher at Lower GFR.

Authors:  Xuehan Zhang; Charles E McCulloch; Feng Lin; Yen-Chung Lin; Isabel Elaine Allen; Nisha Bansal; Alan S Go; Chi-Yuan Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-03       Impact factor: 8.237

7.  The use of the Calvert formula to determine the optimal carboplatin dosage.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Reproducibility of the measurements of creatinine clearance in patients with a stable renal function.

Authors:  Katarzyna Wieczorowska-Tobis; Przemyslaw Guzik; Zofia Niemir; Andrzej Breborowicz; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

9.  Quantitative analysis of drug handling by the kidney using a physiological model of renal drug clearance.

Authors:  I Janků; K Zvára
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.